February 19th 2021
By Tony Hagen
Fresenius Kabi steps into the Canadian market for adalimumab with Idacio.
February 17th 2021
Coherus BioSciences filed a 351(k) biologics license application (BLA) for CHS-1420, an adalimumab biosimilar candidate.
February 16th 2021
The launch of Hyrimoz gives Sandoz 5 biosimilars on the Canadian market. National policies on switching have given biosimilars a tailwind.
February 15th 2021
The marketing of Yuflyma is expected to give Celltrion Healthcare a significant advantage over existing adalimumab biosimilars.
February 13th 2021
Biosimilars, supply chain adjustments, building trust, and international standardization were discussed as means to deliver innovation when it's needed, not after.
February 12th 2021
The Bengaluru, India, company said the fast-acting biosimilar will improve affordability of insulin in Europe, which also faces rising prices and access problems.
February 11th 2021
Lannett and HEC Pharm are developing an insulin aspart biosimilar on the heels of their insulin glargine codevelopment project.
February 7th 2021
China’s regulatory reforms and policy enhancements bode well for a thriving biosimilars industry.
February 5th 2021
Celltrion aims to try a direct marketing approach in Canada to streamline sales of its subcutaneous form of Remsima.
February 3rd 2021
Test your knowledge of biosimilar approvals in China.
